Key result
Empagliflozin reverses HFpEF-related proarrhythmic electrophysiological changes via CaMKII-dependent late sodium current suppression.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for SGLT2i antiarrhythmic effects in HFpEF; leaves open translation beyond murine models.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Donald M. Bers (2022) studied Heart Failure with Preserved Ejection Fraction (HFpEF). Empagliflozin vs. Vehicle (0.01% dimethyl sulfoxide) was evaluated on Late Na+ current (INaL) and action potential duration (APD). Empagliflozin reversed INaL upregulation and proarrhythmic action potential changes in a murine HFpEF model through an indirect, preincubation-dependent mechanism likely involving CaMKII suppression.
Synapse has enriched 10 related papers. Consider them for comparative context: